{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:27:13Z","timestamp":1741667233916,"version":"3.38.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00120-025-02522-8","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:58:41Z","timestamp":1740751121000},"page":"288-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravesikale Therapie des nicht muskelinvasiven Urothelkarzinoms der Harnblase","Intravesical treatment of non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"64","author":[{"given":"Henning","family":"Bahlburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Noldus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2522_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/s1569-9056(19)30462-2","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester\u00a0RJ, Rodr\u00edguez\u00a0O, Hern\u00e1ndez\u00a0V, Turturica\u00a0D, Bauerov\u00e1\u00a0L, Bruins\u00a0HM et\u00a0al (2021) European association of urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. https:\/\/doi.org\/10.1016\/s1569-9056(19)30462-2","journal-title":"Eur Urol"},{"key":"2522_CR2","unstructured":"W\u00f6ckel A et\u00a0al S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms (AWMF-Registernummer: 032\/038OL.Langversion 2.0)"},{"key":"2522_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010","author":"M Babjuk","year":"2022","unstructured":"Babjuk\u00a0M, Burger\u00a0M, Capoun\u00a0O, Cohen\u00a0D, Comp\u00e9rat\u00a0EM, Dominguez Escrig\u00a0JL et\u00a0al (2022) European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"2522_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.05.050","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester\u00a0RJ, Oosterlinck\u00a0W, Holmang\u00a0S, Sydes\u00a0MR, Birtle\u00a0A, Gudjonsson\u00a0S et\u00a0al (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a\u00a0single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2015.05.050","journal-title":"Eur Urol"},{"key":"2522_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000026911.98171.c6","author":"M Huncharek","year":"2001","unstructured":"Huncharek\u00a0M, McGarry\u00a0R, Kupelnick\u00a0B (2001) Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a\u00a0meta-analysis. Anticancer Res. https:\/\/doi.org\/10.1097\/01.coc.0000026911.98171.c6","journal-title":"Anticancer Res"},{"key":"2522_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)64043-8","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle\u00a0A, Jocham\u00a0D, Bock\u00a0PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin\u00a0C for superficial bladder cancer: a\u00a0formal meta-analysis of comparative studies on recurrence and toxicity. J\u00a0Urol. https:\/\/doi.org\/10.1016\/s0022-5347(05)64043-8","journal-title":"J Urol"},{"key":"2522_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.11.049","author":"A B\u00f6hle","year":"2004","unstructured":"B\u00f6hle\u00a0A, Bock\u00a0PR (2004) Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin\u00a0C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. https:\/\/doi.org\/10.1016\/j.urology.2003.11.049","journal-title":"Urology"},{"key":"2522_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200211000-00016","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0APM, Lamm\u00a0DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a\u00a0meta-analysis of the published results of randomized clinical trials. J\u00a0Urol. https:\/\/doi.org\/10.1097\/00005392-200211000-00016","journal-title":"J Urol"},{"key":"2522_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.05.003","author":"JR Oddens","year":"2004","unstructured":"Oddens\u00a0JR, van der Meijden\u00a0APM, Sylvester\u00a0R (2004) One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2004.05.003","journal-title":"Eur Urol"},{"key":"2522_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12340","author":"MH Elmamoun","year":"2014","unstructured":"Elmamoun\u00a0MH, Christmas\u00a0TJ, Woodhouse\u00a0CRJ (2014) Destruction of the bladder by single dose mitomycin\u00a0C for low-stage transitional cell carcinoma (TCC)\u2014avoidance, recognition, management and consent. BJU Int. https:\/\/doi.org\/10.1111\/bju.12340","journal-title":"BJU Int"},{"key":"2522_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.8.597","author":"JLS Au","year":"2001","unstructured":"Au\u00a0JLS, Badalament\u00a0RA, Wientjes\u00a0MG, Young\u00a0DC, Warner\u00a0JA, Venema\u00a0PL et\u00a0al (2001) Methods to improve efficacy of intravesical mitomycin\u00a0C:\u00a0results of a\u00a0randomized phase\u00a0III trial. J\u00a0Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/93.8.597","journal-title":"J Natl Cancer Inst"},{"key":"2522_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2003.12.010","author":"M Kuroda","year":"2004","unstructured":"Kuroda\u00a0M, Niijima\u00a0T, Kotake\u00a0T, Akaza\u00a0H, Hinotsu\u00a0S (2004) Effect of prophylactic treatment with Intravesical Epirubicin on recurrence of superficial bladder cancer\u2014the 6th\u00a0trial of the Japanese urological cancer research group (JUCRG):: a\u00a0randomized trial of Intravesical epirubicin at dose of 20\u202fmg\/40\u202fml, 30\u202fmg\/40\u202fml, 40\u202fmg\/40\u202fml. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2003.12.010","journal-title":"Eur Urol"},{"key":"2522_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.1989.tb05159.x","author":"AAGM Giesbers","year":"1989","unstructured":"Giesbers\u00a0AAGM, Helsdingen\u00a0PJROV, Kramer\u00a0AEJL (1989) Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-comparison of exposure times. Br J Urol. https:\/\/doi.org\/10.1111\/j.1464-410x.1989.tb05159.x","journal-title":"Br J Urol"},{"key":"2522_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.01.015","author":"RJ Sylvester","year":"2008","unstructured":"Sylvester\u00a0RJ, Oosterlinck\u00a0W, Witjes\u00a0JA (2008) The schedule and duration of Intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a\u00a0systematic review of the published results of randomized clinical trials. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2008.01.015","journal-title":"Eur Urol"},{"key":"2522_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)67707-5","author":"DL Lamm","year":"2000","unstructured":"Lamm\u00a0DL, Blumenstein\u00a0BA, Crissman\u00a0JD, Montie\u00a0JE, Gottesman\u00a0JE, Lowe\u00a0BA et\u00a0al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a\u00a0randomized southwest oncology group study. J\u00a0Urol. https:\/\/doi.org\/10.1016\/s0022-5347(05)67707-5","journal-title":"J Urol"},{"key":"2522_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)37316-0","author":"DL Lamm","year":"1992","unstructured":"Lamm\u00a0DL, van der Meijden\u00a0APM, Morales\u00a0A, Brosman\u00a0SA, Catalona\u00a0WJ, Herr\u00a0HW et\u00a0al (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J\u00a0Urol. https:\/\/doi.org\/10.1016\/s0022-5347(17)37316-0","journal-title":"J Urol"},{"key":"2522_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.52","author":"H Zargar","year":"2014","unstructured":"Zargar\u00a0H, Aning\u00a0J, Ischia\u00a0J, So\u00a0A, Black\u00a0P (2014) Optimizing intravesical mitomycin\u00a0C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. https:\/\/doi.org\/10.1038\/nrurol.2014.52","journal-title":"Nat Rev Urol"},{"key":"2522_CR18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2002.00415.x","author":"N Ikeda","year":"2002","unstructured":"Ikeda\u00a0N, Toida\u00a0I, Iwasaki\u00a0A, Kawai\u00a0K, Akaza\u00a0H (2002) Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Gu\u00e9rin (BCG): a\u00a0role of BCG internalization into tumor cells. Int J Urol. https:\/\/doi.org\/10.1046\/j.1442-2042.2002.00415.x","journal-title":"Int J Urol"},{"key":"2522_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602026","author":"RFM Bevers","year":"2004","unstructured":"Bevers\u00a0RFM, Kurth\u00a0KH, Schamhart\u00a0DHJ (2004) Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer. https:\/\/doi.org\/10.1038\/sj.bjc.6602026","journal-title":"Br J Cancer"},{"key":"2522_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000073852.24341.4a","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle\u00a0A, Brandau\u00a0S (2003) Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J\u00a0Urol. https:\/\/doi.org\/10.1097\/01.ju.0000073852.24341.4a","journal-title":"J Urol"},{"key":"2522_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/iai.71.8.4647-4656.2003","author":"H Suttmann","year":"2003","unstructured":"Suttmann\u00a0H, Lehan\u00a0N, B\u00f6hle\u00a0A, Brandau\u00a0S (2003) Stimulation of neutrophil granulocytes with mycobacterium bovis bacillus Calmette-Gu\u00e9rin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis. Infect Immun. https:\/\/doi.org\/10.1128\/iai.71.8.4647-4656.2003","journal-title":"Infect Immun"},{"key":"2522_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)35678-1","author":"TL Ratliff","year":"1993","unstructured":"Ratliff\u00a0TL, Ritchey\u00a0JK, Yuan\u00a0JJJ, Andriole\u00a0GL, Catalona\u00a0WJ (1993) T\u2011cell subsets required for intravesical BCG immunotherapy for bladder cancer. J\u00a0Urol. https:\/\/doi.org\/10.1016\/s0022-5347(17)35678-1","journal-title":"J Urol"},{"key":"2522_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd011935.pub2","author":"S Schmidt","year":"2020","unstructured":"Schmidt\u00a0S, Kunath\u00a0F, Coles\u00a0B, Draeger\u00a0DL, Krabbe\u00a0LM, Dersch\u00a0R et\u00a0al (2020) Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin\u00a0C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd011935.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2522_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.11.016","author":"RL Steinberg","year":"2017","unstructured":"Steinberg\u00a0RL, Brooks\u00a0NA, Thomas\u00a0LJ, Mott\u00a0SL, O\u2019Donnell\u00a0MA (2017) Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non\u2013muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig. https:\/\/doi.org\/10.1016\/j.urolonc.2016.11.016","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2522_CR25","doi-asserted-by":"publisher","DOI":"10.1023\/a:1019507104741","author":"J Palou","year":"2001","unstructured":"Palou\u00a0J, Rodr\u00edguez-Villamil\u00a0L, Andreu-Crespo\u00a0A, Salvador-Bayarri\u00a0J, Vicente-Rodr\u00edguez\u00a0J (2001) Intravesical treatment of severe bacillus Calmette-Guerin cystitis. Int Urol Nephrol. https:\/\/doi.org\/10.1023\/a:1019507104741","journal-title":"Int Urol Nephrol"},{"key":"2522_CR26","unstructured":"Food and Drug Administration (2018) https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and"},{"key":"2522_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.10.008","author":"JC Angulo","year":"2023","unstructured":"Angulo\u00a0JC, \u00c1lvarez-Ossorio\u00a0JL, Dom\u00ednguez-Escrig\u00a0JL, Moyano\u00a0JL, Sousa\u00a0A, Fern\u00e1ndez\u00a0JM et\u00a0al (2023) Hyperthermic mitomycin\u00a0C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC\u20111 trial. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2022.10.008","journal-title":"Eur Urol Oncol"},{"key":"2522_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00147-9","author":"AV Balar","year":"2021","unstructured":"Balar\u00a0AV, Kamat\u00a0AM, Kulkarni\u00a0GS, Uchio\u00a0EM, Boormans\u00a0JL, Roumigui\u00e9\u00a0M et\u00a0al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase\u00a02\u00a0study. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(21)00147-9","journal-title":"Lancet Oncol"},{"key":"2522_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/s1569-9056(19)34697-4","author":"AE Hentschel","year":"2020","unstructured":"Hentschel\u00a0AE, Van Rhijn\u00a0BWG, Br\u00fcndl\u00a0J, Comp\u00e9rat\u00a0EM, Plass\u00a0K, Rodr\u00edguez\u00a0O et\u00a0al (2020) Papillary urothelial neoplasm of low malignant potential (PUN-LMP): still a\u00a0meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Urol Oncol Semin Orig Investig. https:\/\/doi.org\/10.1016\/s1569-9056(19)34697-4","journal-title":"Urol Oncol Semin Orig Investig"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02522-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T17:52:07Z","timestamp":1741629127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02522-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2522"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02522-8","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"9 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"H.\u00a0Bahlburg: Finanzielle Interessen: Deutsche Forschungsgesellschaft (DFG), Walter-Benjamin-Programm, 02\/2023-08\/2024\u00a0| Desitin Arzneimittel GmbH, Referentent\u00e4tigkeit, 11\/2022.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Arzt, Klinik f\u00fcr Urologie, Marien Hospital Herne\u00a0\u2013 Universit\u00e4tsklinikum der Ruhr-Universit\u00e4t Bochum, H\u00f6lkeskampring 40, 44625 Herne\u00a0| Mitgliedschaften: Nordrhein-Westf\u00e4lische Gesellschaft f\u00fcr Urologie, Deutsche Gesellschaft f\u00fcr Urologie, International Bladder Cancer Network. J.\u00a0Noldus: A.\u00a0Finanzielle Interessen: J.\u00a0Noldus gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Klinikdirektor, Klinik f\u00fcr Urologie und Neurourologie, Marien Hospital Herne\u00a0\u2013 Universit\u00e4tsklinikum der Ruhr-Universit\u00e4t Bochum, H\u00f6lkeskampring 40, 44625 Herne. F.\u00a0Roghmann: A.\u00a0Finanzielle Interessen: Referentenhonorare von MSD, Janssen, Merck, Pfizer, BMS, Astellas\u00a0| Reisekostenerstattung von Merck, BMS, Janssen\u00a0| Beratungshonorare von MSD, Janssen, Roche, Merck, Pfizer, BMS, Astellas.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Arzt (Ruhr-Universit\u00e4t Bochum, Marien Hospital Herne, Klinik f\u00fcr Urologie)\u00a0| Vorstandsmitglied (BRIDGE Consortium).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}